This session will highlight the latest breakthroughs and future directions in immunotherapy and monoclonal antibody development for treating cancer, autoimmune diseases, infectious diseases, and more. Leading researchers and industry experts will discuss novel antibody engineering techniques, next-generation checkpoint inhibitors, CAR-T and T-cell therapies, bispecific antibodies, and antibody-drug conjugates (ADCs). The session will also address clinical translation, manufacturing challenges, resistance mechanisms, and strategies to enhance efficacy and safety in patients